Adlai Nortye vs Ensysce Biosciences
ANL and ENSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANL and ENSC compare
Ensysce Biosciences scores higher on the StockData Score (9 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANL | ENSC |
|---|---|---|
| Size and price | ||
| Market cap | – | $8.1M |
| Share price | $10.61 | $0.418 |
| Change, 1 year | 559% | −79.7% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 1.67 | 2.59 |
| Employees | – | 8 |
| StockData Score | ||
| Total score | 0 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.3× |
| P/B | – | 0.3× |
| Fair value | – | $1.73 |
| Margin of safety | – | 75.8% |
| Growth | ||
| Revenue growth (TTM) | – | 37.9% |
| Revenue growth, 5Y average | – | 5.2% |
| Profitability | ||
| Operating margin | −714% (better) | −1477% |
| Net margin | −711% | – |
| FCF margin | −673% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −23.3× (better) | −7157.6× |
| Current ratio | 0.65 | 8.02 (better) |
| Altman Z-score | – | −17.54 |
| Piotroski F-score | 1 | – |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 22.1% | 4.7% |
| Held by insiders | 14.7% | 6.2% |
| Insider net buying, 12 months | −$411K | $444K (better) |
| Short interest, % of float | – | 0.49% |
Go deeper
- ANL stock overview
- ANL income statement
- ANL valuation and score
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.